Browsing Tag
orphan drugs
3 posts
How rare disease medicine access in Africa is moving from ad hoc supply to structured compliance-led programs
How Veld Pharmaceuticals and Chiesi are reshaping rare disease drug access in Africa through compliance-led programs. Read what this means for the sector.
What the CHMP’s positive view on lomitapide reveals about the evolving HoFH treatment landscape in children
See how Chiesi Group’s paediatric lomitapide expansion could reshape HoFH treatment access, payer dynamics, and rare disease growth across Europe.
How Hansa Biopharma’s imlifidase could redefine access for hardest-to-match transplant candidates
Hansa Biopharma seeks FDA approval for imlifidase to expand transplant eligibility in high-risk ESRD patients. See what this filing means for U.S. access.